Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

miR-221 Mediates the Regulation of Phospholamban Expression and Cardiac Contractility by ZBTB20.

Acta physiologica (Oxford, England)·2026
Same author

MicroRNA-221: A Context-Dependent Mediator in Human Diseases-Highlights from Molecular Mechanisms to Clinical Translation.

Cells·2025
Same author

ZBTB20 Regulates SERCA2a Activity and Myocardial Contractility Through Phospholamban.

Circulation research·2024
Same author

The Role of Prohibitin-2 in Diseases.

Frontiers in bioscience (Landmark edition)·2023
Same author

Subcellular Expression Patterns of FKBP Prolyl Isomerase 10 (FKBP10) in Colorectal Cancer and Its Clinical Significance.

International journal of molecular sciences·2023
Same author

Eukaryotic Ribosomal Protein S5 of the 40S Subunit: Structure and Function.

International journal of molecular sciences·2023

Related Experiment Videos

[Salusins and its cardiovascular effects].

An-Jing Ren1, Li Lin, Xiao-Hong Yan

  • 1Department of Pathophysiology, Second Military Medical University, Shanghai 200433, China.

Sheng Li Ke Xue Jin Zhan [Progress in Physiology]
|September 14, 2013
PubMed
Summary

Newly discovered cardiovascular peptides, salusin-alpha and salusin-beta, impact blood pressure, heart rate, and cardiac injury. These peptides, derived from the same precursor, exhibit opposing roles in atherosclerosis development.

Related Experiment Videos

Area of Science:

  • Cardiovascular peptide research
  • Molecular biology of cardiovascular peptides

Context:

  • Salusins are newly identified peptides with significant cardiovascular activity.
  • Salusin-alpha and salusin-beta are derived from a common precursor.
  • These peptides are distributed across various human and rat tissues and organs.

Purpose:

  • To investigate the cardiovascular effects of salusins.
  • To elucidate the distinct roles of salusin-alpha and salusin-beta in cardiovascular function and disease.

Summary:

  • Salusins, including salusin-alpha (28 amino acids) and salusin-beta (20 amino acids), exhibit diverse cardiovascular effects.
  • Observed effects include blood pressure reduction, heart rate deceleration, myocardial contraction inhibition, and reduced ischemic injury.
  • Additionally, salusins promote cardiomyocyte hypertrophy and vascular smooth muscle cell proliferation.
  • Notably, salusin-alpha and salusin-beta play contrasting roles in the pathogenesis of atherosclerosis.

Impact:

  • Provides novel insights into the function of salusins in the cardiovascular system.
  • Highlights the opposing roles of related peptides in a major cardiovascular disease.
  • Offers potential targets for therapeutic interventions in cardiovascular diseases and atherosclerosis.